Altogether, these results suggest that the protease MMP14 can boost the migration of γδ T cells in the ECM-enriched tumor environment, and might thereby help to overcome limitations that hamper γδ T-cell migration in vivo and, ultimately, therapy outcome. This evidence concerns the gene MMP14 and neoplasm.